Standard Usage and Dosage Guidelines for Brivaracetam Tablets

Brivaracetam/Brivaracetam is a new anti-epileptic drug that belongs to the class of selective synaptic vesicle protein 2A (SV2A) ligand drugs. It was developed by UCB Company to control partial seizures and secondary generalized seizures. It is considered an improved version of Levetiracetam and has better neuroselectivity and tolerability. Brivaracetam acts precisely on the synaptic release mechanism to stabilize neuron discharge, thereby effectively reducing the frequency of epileptic seizures. It has become one of the important drugs in the international epilepsy treatment field in recent years.

In clinical applications, Brivaracetam provides a variety of dosage forms, including tablets, oral solutions and injections, and the three can be used interchangeably. This flexibility enables it to meet the needs of patients at different stages, especially when patients are temporarily unable to take oral medication and can switch to intravenous injection in the short term to maintain the therapeutic effect. For adults with epilepsy, the recommended initial oral dose is usually 50 mg twice daily. Based on individual patient tolerance and clinical response, physicians can adjust the dosage range to 25 to 100 mg per dose, for a total daily dose of 50 to 200 mg. Within this dose range, most patients can maintain good tolerance while maintaining good seizure control. If the patient is temporarily unable to take oral medications, the injection can be administered intravenously slowly over 2 to 15 minutes at 50 mg twice a day, with the same dosage as the oral formulation. Intravenous injection is usually used as a short-term alternative to oral administration, and continuous use is recommended for no more than 4 days.

The dosage of pediatric patients needs to be accurately calculated based on body weight, which is the scientific core of brivaracetam dosage design. For children 1 month to 16 years old, the doctor will adjust the dosage according to weight. For children weighing less than 11 kg, the starting dose is 0.75 to 1.5 mg per kilogram twice daily, and the maintenance dose can be increased to 0.75 to 3 mg per kilogram; for children weighing 11 to 20 kg, the starting dose is 0.75 to 1.5 mg per kilogram twice daily. For children weighing 20 to 50 kg, the starting dose is 0.5 to 1 mg per kilogram, and the maintenance dose ranges from 0.5 to 2 mg per kilogram. For people weighing 50 kg or more, the same dosage regimen as for adults is usually used, 25 to 100 mg twice daily. This weight-graded administration method reflects the individualized principle of brivaracetam pharmacokinetics and helps to achieve a balance between optimal efficacy and minimal side effects in different age groups.

Adolescent and adult patients 16 years of age and older typically start with 50 mg twice daily, titrated based on efficacy and tolerability. Studies have shown that Brivaracetam has stable metabolism in the body and is not easily affected by food or other anti-epileptic drugs. Therefore, the taking time is relatively flexible and can be taken with food or on an empty stomach. If combined treatment with other antiepileptic drugs is required, no significant dose adjustment is required, but concomitant use with strong CYP2C19 inhibitors should be avoided to prevent changes in drug concentrations.

During use, doctors will closely monitor the patient's seizure control and adverse reactions, such as drowsiness, dizziness or mild fatigue, which can generally resolve on their own without stopping the medication. If the patient has reduced liver function, the dose needs to be appropriately reduced based on clinical assessment. For patients with renal insufficiency, since brivaracetam is mainly metabolized by the liver, there is usually no need to significantly adjust the dose, but it should still be used under the guidance of a physician.

Reference materials:https://www.briviact.com/